BPI21-006: Timing of NTRK Gene Fusion Testing and Treatment Modifications Following NTRK+ Status Among U.S. Oncologists Treating NTRK+ Patients

Authors:
Landon Z. Marshall Cardinal Health Specialty Solutions, Dublin, OH

Search for other papers by Landon Z. Marshall in
Current site
Google Scholar
PubMed Close
 PharmD, PhD
,
Andrew J. Klink Cardinal Health Specialty Solutions, Dublin, OH

Search for other papers by Andrew J. Klink in
Current site
Google Scholar
PubMed Close
 PhD
,
Abhishek Kavati Bayer U.S. LLC, Whippany, NJ

Search for other papers by Abhishek Kavati in
Current site
Google Scholar
PubMed Close
 PhD
,
Ruth Antoine Bayer U.S. LLC, Whippany, NJ

Search for other papers by Ruth Antoine in
Current site
Google Scholar
PubMed Close
 MBA
,
Sibyl Anderson Bayer U.S. LLC, Whippany, NJ

Search for other papers by Sibyl Anderson in
Current site
Google Scholar
PubMed Close
 MD
, and
Bruce Feinberg Cardinal Health Specialty Solutions, Dublin, OH

Search for other papers by Bruce Feinberg in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 19: Issue 3.5
Online Publication Date:
17 Mar 2021
DOI:
https://doi.org/10.6004/jnccn.2020.7757
Restricted access

Corresponding Author: Landon Z. Marshall, PharmD, PhD
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
Copyright:
Copyright © 2021 by the National Comprehensive Cancer Network 2021
Article Category:
Abstract
Print Publication Date:
20 Mar 2021
Online Publication Date:
17 Mar 2021

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1351 482 89
PDF Downloads 515 0 0
EPUB Downloads 0 0 0